3 Evidence

This appraisal is a review of NICE's guidance TA250. The relevant evidence submitted by the company (Eisai) is the data for the subgroup of patients who had locally advanced or metastatic breast cancer that has progressed after 2 or more chemotherapy regimens for advanced disease, which includes capecitabine (if indicated, referred to as subgroup 2 in their submission). The appraisal committee considered this evidence alongside a review of the company submission by the evidence review group (ERG). See the committee papers for full details of the evidence.

  • National Institute for Health and Care Excellence (NICE)